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The treatment of inflammatory bowel disease (IBD†) recently has been revolutionized by the
introduction of protein-based biologic therapies. However, biologic therapy is complicated by
the requirement for administration with a needle, systemic side effects, and high cost. Par-
ticulate drug delivery systems have been shown to deliver drugs locally to the intestinal mu-
cosa via oral administration. However, these systems have been largely unexplored for the
delivery of biologics due to harsh particle fabrication conditions and the tendency of many
particulate formulations to dissolve in the acidic upper GI tract. We have, therefore, fabri-
cated an inexpensive and non-toxic novel microparticle capable of encapsulating proteins.
We establish that the particle retains its contents at acidic pH and releases them at neutral
pH. We also demonstrate particulate encapsulation of interleukin-10 (IL-10), a protein rele-
vant to the treatment of IBD, at an encapsulation efficiency of 14.3 percent. Such a vehicle
is promising for its oral route of administration and potential to decrease side effects and in-
crease potency of biologics. 
Biologic  therapies  have  greatly  im-
proved the treatment of inflammatory bowel
disease (IBD), although their use can be
limited by significant side effects, high cost,
and the requirement of injection or infusion
[1,2]. In addition, some promising thera-
pies, such as interleukin-10 (IL-10), have
proven ineffective due to inadequate local
tissue concentrations when delivered sys-
temically  [3,4].  However,  recent  studies
have demonstrated increased potency and
decreased systemic toxicity of colitis thera-
pies that are delivered locally by such carri-
ers as drug-loaded micro- and nanoparticles
[5,6].
Particulate drug delivery vehicles are
especially well-suited to treating IBD be-
cause they selectively accumulate in areas
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trobenzene sulfonic acid.of intestinal inflammation when delivered
orally. This allows for the local delivery of
therapeutics to areas of inflammation with-
out the need to target ligands on the particle
surface [7]. However, particulate delivery of
biologics has remained largely unexplored,
given the harsh physical conditions often in-
volved in particle fabrication, and delivery
to the upper GI tract has been limited by the
tendency of particles to degrade in its low-
pH environment. 
Here,  we  designed  and  fabricated  a
novel particulate drug-delivery platform in
order to encapsulate protein biologic thera-
pies, protecting these drugs from the low pH
of the upper GI tract and delivering them
specifically to inflammatory lesions in the
lower GI tract. Potential therapeutic use of
this vehicle includes the oral administration
and subsequent local delivery of both novel
and existing Food and Drug Administration
(FDA)-approved  biologic  therapies  cur-
rently available only in systemically deliv-
ered, injectable forms. Local delivery of
biologics via such a targeted platform could
potentially increase the efficacy, decrease
the side effects, and decrease the therapeutic
dose of biologics used to treat IBD.
We designed a particle composed of an
aqueous gelatin core surrounded by a coat-
ing of the commercially available pH-re-
sponsive  polymer  Eudragit  FS30D  (gift
from Evonik Industries, Darmstadt, Ger-
many) (Figure 1a). A protein therapeutic
may be contained within the aqueous core
and is easily incorporated during fabrication
using  a  standard  water/oil/water  double
emulsion technique that has been described
previously [8]. Briefly, a solution of the en-
capsulant protein in 20 wt% gelatin was
added drop wise to a solution of 0.5 mg/ml
Eudragit FS30D in dichloromethane while
vortexing. This water/oil emulsion was then
added to a 5 percent aqueous solution of
polyvinyl alcohol while vortexing, which
was subsequently added to a large volume
of phosphate buffered saline (PBS) acidified
with hydrochloric acid to approximately pH
4. The solution was stirred for 1 hour to
allow for dichloromethane evaporation, fol-
lowed by washing of the particles with acid-
ified PBS and storage at -80ﾺC.
The particles were visualized by scan-
ning electron microscopy, and size distribu-
tion was determined using ImageJ analysis
software (National Institutes of Health). Vi-
sualization revealed round discreet particles
with smooth surface morphology (Figure
1b). The particle size distribution is pre-
sented in Figure 1c. 
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Figure 1. Characterization of microparticles. a: schematic of particle design; b: scan-
ning electron micrograph of particles; c: particle size distribution; d: encapsulant release
as a function of pH.Drug release as a function of pH was
determined by encapsulating bovine serum
albumin conjugated to rhodamine B (BSA-
Rho) within the aqueous core. Particles were
incubated on a rotary shaker at 37ﾺC in cit-
rate buffer for 2 hours at pH 2, 2 hours at pH
5, and finally 2 hours at pH 7, mimicking the
pH environments encountered by particles
delivered via the oral route. Particles were
collected hourly via centrifugation and dis-
solved in dimethyl sulfoxide. BSA-Rho re-
lease was then determined via fluorescence
spectroscopy  (Figure  1d). After  2  and  4
hours, the particles were pelleted, washed,
and re-suspended in the appropriate buffer. A
robust pH response was observed with <10
percent BSA-Rho released under acidic con-
ditions and a rapid burst release of >80 per-
cent under neutral conditions, demonstrating
the platform’s ability to deliver drugs to the
lower GI tract via the oral route.
To establish the pertinence of our sys-
tem to IBD, we chose to encapsulate IL-10
(BD Pharmingen, Franklin Lakes, N.J.), an
anti-inflammatory cytokine that has shown
promise as an IBD therapy when delivered
locally [9,10]. Particles containing IL-10
were fabricated using the techniques de-
scribed above, washed three times in acidi-
fied PBS to remove non-encapsulated IL-10,
and subsequently dissolved in bicarbonate
buffer of approximately pH 9 in order to re-
lease any IL-10 encapsulated within the par-
ticle. IL-10 in the supernatant was quantified
via sandwich enzyme linked immunosorbent
assay (ELISA) (BD Biosciences, Franklin
Lakes, N.J.). The IL-10 encapsulation effi-
ciency was determined to be 14.3 percent,
demonstrating the ability to encapsulate pro-
teins relevant to the treatment of IBD in our
particulate system.
While detection via ELISA confirms
the presence of IL-10, it does not necessar-
ily guarantee its bioactivity. Further work,
therefore, includes experiments to ensure the
preservation of IL-10’s anti-inflammatory
activity subsequent to release from the par-
ticle at neutral pH in vitro. Additional future
studies include in vivo biodistribution stud-
ies and toxicity screens. Finally, the advan-
tage  of  our  novel  platform  must  be
determined by comparing it against freely
administered IL-10 in an animal model of
colitis, such as the acute trinitrobenzene sul-
fonic acid (TNBS) administration model or
the chronic CD4CD45RBhi T-cell transfer
model [11].
In conclusion, Eudragit-coated gelatin
microparticles are easily fabricated from in-
expensive non-toxic materials. Particle fab-
rication is a highly reproducible and flexible
process allowing for the encapsulation of
hydrophilic therapeutic agents within the
aqueous core, including protein-based bio-
logic drugs. The strong resistance of the par-
ticle to acidic degradation and its prompt
dissolution in neutral environments demon-
strate its feasibility for targeted colonic drug
delivery via the oral route. Such a platform
potentially could be used in the clinic to in-
crease the efficacy, decrease the side effects,
and  ease  the  administration  of  currently
available biologics. It also could be used to
deliver promising new biologic therapies,
such as IL-10, to the intestinal mucosa. Fur-
thermore, our platform may accommodate
the packaging and subsequent targeted de-
livery of several different biologics with
synergistic mechanisms of action simulta-
neously within the same particle. This novel
pH-responsive particulate drug delivery ve-
hicle, therefore, represents a promising new
modality for the treatment of IBD.
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